Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21N5O4.C6H5NO2 |
Molecular Weight | 434.4463 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CN=CC=C1.CN(CCO)CC(O)CN2C=NC3=C2C(=O)N(C)C(=O)N3C
InChI
InChIKey=GEPMAHVDJHFBJI-UHFFFAOYSA-N
InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)
Molecular Formula | C6H5NO2 |
Molecular Weight | 123.1094 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C13H21N5O4 |
Molecular Weight | 311.3369 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Xanthinol (xanthinol nicotinate) is a xanthine derivative, peripheral vasodilator agent. It exerts it`s pharmacological action by acting as a vasodilator and improves blood flow to brain, arteries, and to the periphery. It increases brain glucose metabolism and thus improves brain ATP levels. It stimulates memory and concentration elevates brain energy levels. Indications for Xanthinol Nicotinate:
1. Peripheral vascular sclerosis
2. Cerebral circulatory disorders
3. Arteriosclerosis
4. Endarteritis obliterans
5. Short term memory disorders
6. Mental flagging
7. Anti ageing memory support
8. Diabetic angiopathy
9. Diabetic gangrene
10. Hyperlipidaemia
11. Intermittent claudication
Side Effects of Xanthinol Nicotinate:
1. Flushing
2. Feeling of warmth
3. Nausea
4. Heart burn
5. Vomiting
6. Itching of skin
For 30 years, Xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. Xanthinol nicotinate is also helpful in the management of leg ulcers associated with haemoglobinopathies.
Xanthinol was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. The positively charged xanthinol ion is thought to help the transportation of the nicotinic acid into the cell since the later cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to present influence in the cell metabolism through the nucleotides NAD and NADP. Also, the nicotinic acid is a coenzyme for a lot of proteins involved in tissue respiration (Embden-Meyerhof and citrate cycle). The effect of xanthinol nicotinate causes an increase in glucose metabolism and energy gain.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. |
|||
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. Launch Date7.2567357E11 |
Sample Use Guides
Typical Dosage for Xanthinol Nicotinate
Oral: 300mg 8th hourly. Increases the dosage up to 600mg 8th hourly if required.
Maximum dose: 1800mg/day.
I.V. or I.M.: 300mg.
Maximum dose: 900mg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26718554
HUASMCs were treated with different concentrations of Xanthinol (xanthinol nicotinate) (0, 2.76, 27.6 or 276 uM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:00:11 UTC 2023
by
admin
on
Fri Dec 15 19:00:11 UTC 2023
|
Record UNII |
8G60H12X2D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
||
|
WHO-VATC |
QC04AD02
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
||
|
DSLD |
3116 (Number of products:10)
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
||
|
WHO-ATC |
C04AD02
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
113217
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
9912
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
DTXSID0023743
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
C152928
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
8G60H12X2D
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
1492
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
207-115-7
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
DBSALT001141
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
11358
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | RxNorm | ||
|
m11528
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB00097MIG
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
XANTINOL NICOTINATE
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
100000092586
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY | |||
|
437-74-1
Created by
admin on Fri Dec 15 19:00:11 UTC 2023 , Edited by admin on Fri Dec 15 19:00:11 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
ACTIVE MOIETY |